SIGA Technologies announced that it has been awarded a contract by the Canadian Department of National Defence (DND) valued at up to $15 million. This contract focuses on the provision of oral TPOXX, an antiviral medication designed for the treatment of smallpox. The contract runs through 2031, emphasizing the Canadian government's commitment to maintaining stockpiles of effective medical countermeasures against potential biological threats.
TPOXX, also known as tecovirimat, is crucial in ensuring preparedness for smallpox outbreaks, particularly in the context of bioterrorism or accidental releases. The World Health Organization declared smallpox eradicated in 1980; however, stocks of the virus remain under tight security in laboratories. This highlights the ongoing need for effective treatments, such as TPOXX, to combat any possible resurgence attempts.
The deal with SIGA underscores a strategic effort by Canada to bolster its public health infrastructure and ensure the safety of its citizens through comprehensive risk management concerning infectious diseases. There is ongoing interest in effective treatments as Canada continues to navigate health security challenges in an evolving global landscape.
Analyzed Canadian Outlets (1)
1 headline